These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 17157365)
1. HPV16 and increased risk of recurrence after treatment for CIN. Gök M; Coupé VM; Berkhof J; Verheijen RH; Helmerhorst TJ; Hogewoning CJ; Snijders PJ; Meijer CJ Gynecol Oncol; 2007 Feb; 104(2):273-5. PubMed ID: 17157365 [TBL] [Abstract][Full Text] [Related]
2. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation. Leeman A; Ebisch RMF; Kasius A; Bosgraaf RP; Jenkins D; van de Sandt MM; de Strooper LMA; Heideman DAM; Snijders PJF; Massuger LFAG; Bekkers RLM; Meijer CJLM; van Kemenade FJ; Quint WGV; Melchers WJG Gynecol Oncol; 2018 Nov; 151(2):311-318. PubMed ID: 30219239 [TBL] [Abstract][Full Text] [Related]
3. Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway. Vintermyr OK; Iversen O; Thoresen S; Quint W; Molijn A; de Souza S; Rosillon D; Holl K Gynecol Oncol; 2014 May; 133(2):159-66. PubMed ID: 24631451 [TBL] [Abstract][Full Text] [Related]
4. Population fraction of cervical neoplasia attributable to high-risk human papillomaviruses. Laukkanen P; Läärä E; Koskela P; Pukkala E; Virkkunen H; Lehtinen M Future Oncol; 2010 May; 6(5):709-16. PubMed ID: 20465386 [TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia. Kudoh A; Sato S; Itamochi H; Komatsu H; Nonaka M; Sato S; Chikumi J; Shimada M; Oishi T; Kigawa J; Harada T Int J Clin Oncol; 2016 Jun; 21(3):580-7. PubMed ID: 26614089 [TBL] [Abstract][Full Text] [Related]
6. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. Kjær SK; Frederiksen K; Munk C; Iftner T J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605 [TBL] [Abstract][Full Text] [Related]
7. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. Massad LS; Xie X; Burk RD; D'Souza G; Darragh TM; Minkoff H; Colie C; Burian P; Palefsky J; Atrio J; Strickler HD Am J Obstet Gynecol; 2016 Mar; 214(3):354.e1-6. PubMed ID: 26433170 [TBL] [Abstract][Full Text] [Related]
8. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084 [TBL] [Abstract][Full Text] [Related]
9. Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management. Castle PE; Aslam S; Behrens C Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1595-1599. PubMed ID: 27587789 [TBL] [Abstract][Full Text] [Related]
10. Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: A large population-based study. Wu P; Xiong H; Yang M; Li L; Wu P; Lazare C; Cao C; Gao P; Meng Y; Zhi W; Lin S; Hu J; Wei J; Ma D; Liu J; Yin P; Xing H Gynecol Oncol; 2019 Dec; 155(3):436-443. PubMed ID: 31604662 [TBL] [Abstract][Full Text] [Related]
11. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study). Luttmer R; De Strooper LM; Berkhof J; Snijders PJ; Dijkstra MG; Uijterwaal MH; Steenbergen RD; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; Van Baal WM; Graziosi PG; Quint WG; Heideman DA; Meijer CJ Int J Cancer; 2016 Feb; 138(4):992-1002. PubMed ID: 26317579 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status]. Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846 [No Abstract] [Full Text] [Related]
13. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan. Chang CL; Ho SC; Su YF; Juan YC; Huang CY; Chao AS; Hsu ZS; Chang CF; Fwu CW; Chang TC Gynecol Oncol; 2021 May; 161(2):429-435. PubMed ID: 33757653 [TBL] [Abstract][Full Text] [Related]
14. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225 [TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Berkhof J; Bulkmans NW; Bleeker MC; Bulk S; Snijders PJ; Voorhorst FJ; Meijer CJ Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1268-73. PubMed ID: 16835322 [TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Castle PE; Schiffman M; Wheeler CM; Wentzensen N; Gravitt PE Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1675-81. PubMed ID: 20615885 [TBL] [Abstract][Full Text] [Related]
17. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population. Leeman A; Del Pino M; Marimon L; Torné A; Ordi J; Ter Harmsel B; Meijer CJLM; Jenkins D; Van Kemenade FJ; Quint WGV Int J Cancer; 2019 Jan; 144(1):160-168. PubMed ID: 30098013 [TBL] [Abstract][Full Text] [Related]
18. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Kocken M; Helmerhorst TJ; Berkhof J; Louwers JA; Nobbenhuis MA; Bais AG; Hogewoning CJ; Zaal A; Verheijen RH; Snijders PJ; Meijer CJ Lancet Oncol; 2011 May; 12(5):441-50. PubMed ID: 21530398 [TBL] [Abstract][Full Text] [Related]
19. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519 [TBL] [Abstract][Full Text] [Related]
20. Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease. Babion I; De Strooper LMA; Luttmer R; Bleeker MCG; Meijer CJLM; Heideman DAM; Wilting SM; Steenbergen RDM Epigenetics; 2019 Jun; 14(6):558-567. PubMed ID: 30955437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]